Achieving Viral Suppression in 90% of People Living With Human Immunodeficiency Virus on Antiretroviral Therapy in Low- and Middle-Income Countries: Progress, Challenges, and Opportunities

被引：40

作者：

Nachega, Jean B. ^{[1
,2
,3
,4
,5
,6
,7
]}

Sam-Agudu, Nadia A. ^{[8
,9
,10
]}

Mofenson, Lynne M. ^{[11
]}

Schechter, Mauro ^{[12
]}

Mellors, John W. ^{[13
]}

机构：

[1] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, 130 DeSoto St,503 Parran Hall, Pittsburgh, PA 15260 USA

[2] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis, Pittsburgh, PA USA

[3] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Microbiol, Pittsburgh, PA USA

[4] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA

[5] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA

[6] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Med, Cape Town, South Africa

[7] Stellenbosch Univ, Fac Med & Hlth Sci, Ctr Infect Dis, Cape Town, South Africa

[8] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA

[9] Inst Human Virol Nigeria, Int Res Ctr Excellence, Abuja, Nigeria

[10] Univ Cape Coast, Sch Med Sci, Dept Paediat, Cape Coast, Ghana

[11] Elizabeth Glaser Pediat AIDS Fdn, Washington, DC USA

[12] Univ Fed Rio de Janeiro, Projeto Praca Onze, Rio De Janeiro, Brazil

[13] Univ Pittsburgh, Sch Med, Div Infect Dis, Pittsburgh, PA USA

来源：

CLINICAL INFECTIOUS DISEASES | 2018年 / 66卷 / 10期

基金：

美国国家卫生研究院;

关键词：

human immunodeficiency virus (HIV); 90-90-90; antiretroviral therapy (ARV); viral suppression; low- and middle-in-come countries (LMICs); ADHERENCE CLUBS; INJECT DRUGS; HIV; INITIATION; CHILDREN; CARE; ADULTS; WOMEN; RISK;

D O I：

10.1093/cid/ciy008

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Although significant progress has been made, the latest data from low- and middle-income countries show substantial gaps in reaching the third "90%" (viral suppression) of the UNAIDS 90-90-90 goals, especially among vulnerable and key populations. This article discusses critical gaps and promising, evidence-based solutions. There is no simple and/or single approach to achieve the last 90%. This will require multifaceted, scalable strategies that engage people living with human immunodeficiency virus, motivate long-term treatment adherence, and are community-entrenched and -supported, cost-effective, and tailored to a wide range of global communities.

引用

页码：1487 / 1491

页数：5

共 39 条

[1]

[Anonymous], REG MAPS TREATM CASC

[2]

[Anonymous], S AFRICAN HLTH MONIT

[3]

[Anonymous], POP BAS HIV IMP ASS

[4]

[Anonymous], C RETR OPP INF 13 16

[5]

[Anonymous], 2017, J ACQUIR IMMUNE DEFI

[6]

[Anonymous], J INT AIDS SOC S7

[7]

[Anonymous], PROGR 90 90 90 TARG

[8] Central Nervous System Immune Reconstitution Inflammatory Syndrome [J].

Bahr, Nathan ;

Boulware, David R. ;

Marais, Suzaan ;

Scriven, James ;

Wilkinson, Robert J. ;

Meintjes, Graeme .

CURRENT INFECTIOUS DISEASE REPORTS, 2013, 15 (06) :583-593

[9] Adherence clubs for long-term provision of antiretroviral therapy: cost-effectiveness and access analysis from Khayelitsha, South Africa [J].

Bango, Funeka ;

Ashmore, John ;

Wilkinson, Lynne ;

van Cutsem, Gilles ;

Cleary, Susan .

TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2016, 21 (09) :1115-1123

[10] Suboptimal Viral Suppression Rates Among HIV-Infected Children in Low- and Middle-Income Countries: A Meta-analysis [J].

Boerma, Ragna S. ;

Boender, T. Sonia ;

Bussink, Anton P. ;

Calis, Job C. J. ;

Bertagnolio, Silvia ;

de Wit, Tobias F. Rinke ;

van Hensbroek, Michael Boele ;

Sigaloff, Kim C. E. .

CLINICAL INFECTIOUS DISEASES, 2016, 63 (12) :1645-1654

← 1 2 3 4 →